Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shin-Etsu Completes Takeover Bid For CIRES
Shin-Etsu Chemical has completed the procedures required to make its affiliate CIRES a wholly-owned subsidiary of Shin-Etsu. Earlier in December 10, 2008, Shin-Etsu announced its plan to make
Shin-Etsu Chemical has completed the procedures required to make its affiliate CIRES a wholly-owned subsidiary of Shin-Etsu. Earlier in December 10, 2008, Shin-Etsu announced its plan to make
Centrix, a specialty pharmaceutical company focused on Pediatrics and Women’s Health, is all set to launch Clofera during the fourth quarter. Clofera is indicated for the temporary relief
DOR’s revenues, for the second quarter of 2009, were approximately $0.3m compared to $0.5m for the second quarter of 2008. Revenues for the first half of 2009 were
FDA has approved DNage’s Investigational New Drug application for Prodarsan, allowing the company to initiate a clinical trial in children suffering from Cockayne Syndrome (CS). DNage is a
Hard to Treat Diseases (HTDS Medical) has reported the progress being made with the experimental findings to aid in the suppression or ultimately the cure of Multiple Sclerosis,
GSK has issued an update on its progress to develop a vaccine against the Pandemic (H1N1) 2009 influenza virus. The company has also commenced the clinical development program
Ziopharm has reported that the enrollment in the palifosfamide (Zymafosk or ZIO-201) phase II trial in metastatic or unresectable soft tissue sarcoma, continues in a planned manner. Reportedly,
Barr Laboratories has initiated a voluntary recall of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate 20mg tablets, 100 count bottles, lot number 311756. The product is
Biostar Pharmaceuticals has posted revenue of $13.2m for the second quarter of 2009, an increase of 40.6% compared to $9.4m for the second quarter of 2008. The company
Ziopharm has reported its financial results for the quarter ended June 30, 2009. The company reported a net loss of $2.4m, or $(0.11) per share, for the second